Home › Companies › Fulcrum Therapeutics, Inc. › 2025-2026

Fulcrum Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Fulcrum Therapeutics, Inc.’s Form 8-K, filed 2026-06-25 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
166Asset managers
939Fund votes
2026-06-24Meeting date

Proxy season: 2024-2025 2025-2026

Explore Fulcrum Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Fulcrum Therapeutics, Inc.

These tallies are Fulcrum Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-25 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Fulcrum Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-24
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sonja Banks	43,187,717	--	--	10,601,385	5,062,117	Majority: yes
Elect Director: Alan Ezekowitz	52,317,282	--	--	1,471,820	5,062,117	Majority: yes
Elect Director: Colin Hill	52,363,595	--	--	1,425,507	5,062,117	Majority: yes
Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.	50,735,617	3,026,397	27,088	--	5,062,117	Majority: yes
Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.	58,793,645	36,178	21,396	--	0	Majority: yes

Source: Fulcrum Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-25 — read the filing on EDGAR.

How asset managers voted at the Fulcrum Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 166 asset managers that disclosed a Fulcrum Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Fulcrum Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. A non-binding advisory vote to approve the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 50,735,617AGAINST: 3,026,397

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders approved, on a non-binding advisory basis, the compensation of Fulcrum's named executive officers.”): 50,735,617 for, 3,026,397 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,633,321 outstanding shares: 76% for, 5% against (81% of the company cast a for/against vote).

The 164 asset managers below cast 93% of the shares they voted on this item FOR (42,886,474 for, 3,065,689 against).

FOR 93%

FOR: 42,886,474 (93.3%)AGAINST: 3,065,689 (6.7%)ABSTAIN: 24,487 (0.1%)

Largest asset managers voting on “A non-binding advisory vote to approve the compensation of our named executive officers;” at Fulcrum Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
MONTANOVA CAPITAL, LLC	6,463,818	0	For
RA CAPITAL MANAGEMENT, L.P.	6,053,960	0	For
BlackRock	5,064,170	22,647	For
Vanguard	3,606,938	1	For
Nantahala Capital Management, LLC	2,430,153	0	For
Siren, L.L.C.	2,400,000	0	For
Aberdeen	0	2,211,953	Against
GEODE CAPITAL MANAGEMENT, LLC	1,367,792	0	For
State Street	1,341,322	4,039	For
Fidelity	1,316,063	0	For
BRAIDWELL LP	1,002,718	0	For
Point72	996,763	0	For
Charles Schwab	853,940	0	For
Citadel	778,602	0	For
ORBIMED ADVISORS LLC	728,620	0	For
Vestal Point Capital, LP	725,246	0	For
Connor, Clark & Lunn Investment Management Ltd.	598,870	0	For
DE Shaw	597,099	0	For
Alyeska Investment Group, L.P.	0	453,914	Against
AQR	438,357	0	For
Dimensional	407,946	0	For
ACADIAN ASSET MANAGEMENT LLC	396,499	2,386	For
Northern Trust	373,873	2,813	For
American Century	0	312,484	Against
Bessemer Trust CO of Delaware, N.A.	292,760	0	For

Showing the 25 largest of 164 asset managers. See all 164 in the interactive database.

2. Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Alan Ezekowitz

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 52,317,282WITHHELD: 1,471,820

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Alan Ezekowitz”): 52,317,282 for, 1,471,820 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,633,321 outstanding shares: 79% for, 2% withheld (81% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,169,393 for, 0 against).

FOR 97%

FOR: 9,169,393 (96.6%)ABSTAIN: 326,002 (3.4%)

Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,243,199	4,614	For
BlackRock	2,827,014	0	For
Fidelity	1,253,326	0	For
Charles Schwab	426,963	0	For
State Street	343,783	106	For
Dimensional	0	252,690	Abstain
American Century	156,242	0	For
TIAA	129,618	0	For
Simplify Exchange Traded Funds	116,834	0	For
Equitable	94,568	18,660	For
QUANTITATIVE MASTER SERIES LLC	85,781	0	For
Goldman Sachs	75,194	0	For
Lincoln Financial	52,548	10,042	For
Northern Trust	43,896	0	For
Russell Investments	33,673	0	For
Brighthouse	19,248	14,329	For
AIG/SunAmerica	29,462	0	For
Global X	25,920	0	For
Bridge Builder Trust	25,481	0	For
ProShares	25,456	0	For
MASTER INVESTMENT PORTFOLIO	24,078	0	For
Pacific Life	22,550	0	For
CLEARWATER INVESTMENT TRUST	20,361	0	For
John Hancock	14,642	0	For
Jackson National	0	14,631	Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

3. Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Colin Hill

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 52,363,595WITHHELD: 1,425,507

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Colin Hill”): 52,363,595 for, 1,425,507 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,633,321 outstanding shares: 79% for, 2% withheld (81% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (9,174,462 for, 0 against).

FOR 97%

FOR: 9,174,462 (96.6%)ABSTAIN: 320,932 (3.4%)

Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,247,809	3	For
BlackRock	2,827,014	0	For
Fidelity	1,253,326	0	For
Charles Schwab	426,963	0	For
State Street	343,889	0	For
Dimensional	0	252,690	Abstain
American Century	156,242	0	For
TIAA	129,618	0	For
Simplify Exchange Traded Funds	116,834	0	For
Equitable	94,568	18,660	For
QUANTITATIVE MASTER SERIES LLC	85,781	0	For
Goldman Sachs	75,194	0	For
Lincoln Financial	52,548	10,042	For
Northern Trust	43,896	0	For
Russell Investments	33,673	0	For
Brighthouse	19,248	14,329	For
AIG/SunAmerica	29,462	0	For
Global X	25,920	0	For
Bridge Builder Trust	25,481	0	For
ProShares	25,456	0	For
MASTER INVESTMENT PORTFOLIO	24,078	0	For
Pacific Life	22,550	0	For
CLEARWATER INVESTMENT TRUST	20,361	0	For
John Hancock	14,642	0	For
Jackson National	0	14,631	Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

4. Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term expiring at the 2029 annual meeting of stockholders: Sonja Banks

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

80% Majority: yes · of votes cast

FOR 80%WITHHELD 20%

FOR: 43,187,717WITHHELD: 10,601,385

Fulcrum Therapeutics, Inc.’s own tally for this item (“Elect Director: Sonja Banks”): 43,187,717 for, 10,601,385 withheld, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,633,321 outstanding shares: 65% for, 16% withheld (81% of the company cast a for/withheld vote).

The 50 asset managers below cast 100% of the shares they voted on this item FOR (8,728,837 for, 0 against).

FOR 92%8%

FOR: 8,728,837 (91.9%)ABSTAIN: 766,558 (8.1%)

Largest asset managers voting on “Election of three Class I directors, nominated by our board of directors, each to serve for a three-year term ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	3,209,493	38,319	For
BlackRock	2,827,014	0	For
Fidelity	1,236,032	17,294	For
Charles Schwab	426,963	0	For
State Street	343,622	267	For
Dimensional	0	252,690	Abstain
American Century	0	156,242	Abstain
TIAA	129,618	0	For
Simplify Exchange Traded Funds	116,834	0	For
Equitable	94,568	18,660	For
QUANTITATIVE MASTER SERIES LLC	85,781	0	For
Goldman Sachs	75,194	0	For
Lincoln Financial	27,900	34,690	Abstain
Northern Trust	0	43,896	Abstain
Russell Investments	33,673	0	For
Brighthouse	0	33,577	Abstain
AIG/SunAmerica	0	29,462	Abstain
Global X	25,920	0	For
Bridge Builder Trust	25,481	0	For
ProShares	0	25,456	Abstain
MASTER INVESTMENT PORTFOLIO	24,078	0	For
Pacific Life	22,550	0	For
CLEARWATER INVESTMENT TRUST	0	20,361	Abstain
John Hancock	0	14,642	Abstain
Jackson National	0	14,631	Abstain

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

5. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; and

AUDIT-RELATEDMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 58,793,645AGAINST: 36,178

Fulcrum Therapeutics, Inc.’s own tally for this item (“Fulcrum's stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 58,793,645 for, 36,178 against, per its Form 8-K filed 2026-06-25 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 66,633,321 outstanding shares: 88% for, 0.1% against (88% of the company cast a for/against vote).

The 50 asset managers below cast 99.9% of the shares they voted on this item FOR (9,481,011 for, 55 against).

FOR 99.8%

FOR: 9,481,011 (99.8%)AGAINST: 55 (0.0%)ABSTAIN: 14,329 (0.2%)

Largest asset managers voting on “Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for ” at Fulcrum Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	3,247,812	0	0	For
BlackRock	2,827,014	0	0	For
Fidelity	1,253,326	0	0	For
Charles Schwab	426,963	0	0	For
State Street	343,834	55	0	For
Dimensional	252,690	0	0	For
American Century	156,242	0	0	For
TIAA	129,618	0	0	For
Simplify Exchange Traded Funds	116,834	0	0	For
Equitable	113,228	0	0	For
QUANTITATIVE MASTER SERIES LLC	85,781	0	0	For
Goldman Sachs	75,194	0	0	For
Lincoln Financial	62,590	0	0	For
Northern Trust	43,896	0	0	For
Russell Investments	33,673	0	0	For
Brighthouse	19,248	0	14,329	For
AIG/SunAmerica	29,462	0	0	For
Global X	25,920	0	0	For
Bridge Builder Trust	25,481	0	0	For
ProShares	25,456	0	0	For
MASTER INVESTMENT PORTFOLIO	24,078	0	0	For
Pacific Life	22,550	0	0	For
CLEARWATER INVESTMENT TRUST	20,361	0	0	For
John Hancock	14,642	0	0	For
Jackson National	14,631	0	0	For

Showing the 25 largest of 50 asset managers. See all 50 in the interactive database.

Showing the 5 reported items with the widest manager coverage, of 6 in total. View every item.

Largest Fulcrum Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Fulcrum Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 66,633,321 shares outstanding at the time of that meeting.

Top Fulcrum Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	MONTANOVA CAPITAL, LLC	9.70%
2	RA CAPITAL MANAGEMENT, L.P.	9.09%
3	BlackRock	7.63%
4	Vanguard	5.41%
5	Nantahala Capital Management, LLC	3.65%
6	Siren, L.L.C.	3.60%
7	Aberdeen	3.32%
8	GEODE CAPITAL MANAGEMENT, LLC	2.05%
9	State Street	2.02%
10	Fidelity	1.98%

Reported Fulcrum Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Fulcrum Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
RA Capital Management, L.P.	9.98%	DEF14A
Suvretta Capital Management, LLC	9.27%	DEF14A
Nantahala Capital Management, LLC	8.52%	DEF14A
BlackRock	8.09%	13F
TCG Crossover GP II, LLC	7.50%	DEF14A
BANK OF AMERICA CORP /DE/	6.71%	13G
Montanova Capital, LLC	5.52%	13G
Vanguard Group	5.34%	13F
Alex C. Sapir	3.15%	DEF14A
Point72	3.11%	13F

Percentages above are of 66,633,321 shares outstanding, as reported by Fulcrum Therapeutics, Inc. on its Form 10-Q dated 2026-04-20 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Fulcrum Therapeutics, Inc.’s 10-Q dated 2026-04-20. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Fulcrum Therapeutics, Inc.'s shareholder meeting held 2026-06-24, in the 2025-2026 proxy season, 166 asset managers reported how they voted in their SEC Form N-PX filings, covering 939 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — A non-binding advisory vote to approve the compensation of our named executive officers; — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Fulcrum Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-25.

Fulcrum Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).